Lichter Jay 4

Accession 0001415889-24-025601

CIK 0001817713other

View on SEC.gov Company Profile

Filed

Oct 23, 8:00 PM ET

Accepted

Oct 24, 4:15 PM ET

Size

24.0 KB

Accession

0001415889-24-025601

Insider Transaction Report

Form 4

Period: 2024-09-13

Janux Therapeutics, Inc.JANX

Lichter Jay

Director10% Owner

Transactions

Exercise/Conversion
Stock Option (right to buy)
2024-09-13−778→ 11,308 total
Exercise: $13.22Exp: 2027-07-19→ Common Stock (778 underlying)
Exercise/Conversion
Common Stock
2024-09-13$17.00/sh+1,868$31,756→ 8,868 total
Exercise/Conversion
Common Stock
2024-09-13$10.73/sh+778$8,348→ 9,646 total
Exercise/Conversion
Common Stock
2024-09-13$39.80/sh+391$15,562→ 10,815 total
Exercise/Conversion
Stock Option (right to buy)
2024-09-13−778→ 11,308 total
Exercise: $10.73Exp: 2027-07-19→ Common Stock (778 underlying)
Exercise/Conversion
Stock Option (right to buy)
2024-09-13−391→ 7,682 total
Exercise: $39.80Exp: 2027-07-19→ Common Stock (391 underlying)
Exercise/Conversion
Common Stock
2024-09-13$13.22/sh+778$10,285→ 10,424 total
Sale
Common Stock
2024-09-13$46.68/sh−3,815$178,084→ 7,000 total
Exercise/Conversion
Stock Option (right to buy)
2024-09-13−1,868→ 27,138 total
Exercise: $17.00Exp: 2027-07-19→ Common Stock (1,868 underlying)

Holdings

Common Stock
(indirect: By Avalon BioVentures I, LP)
573,227
Common Stock
(indirect: By Avalon BioVentures SPV I, L.P.)
3,021,414
Common Stock
(indirect: By Avalon Ventures XI, L.P.)
2,959,175

Footnotes (4)

[F1]The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. The Reporting Person is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. The Reporting Persons disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
[F2]The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. The Reporting Person is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. The Reporting Persons disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
[F3]The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. The Reporting Person is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. The Reporting Persons disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
[F4]Immediately exercisable.

Documents

1 file

4
form4-10242024_041001.xmlPrimary

Issuer

Janux Therapeutics, Inc.

CIK 0001817713

→

Entity typeother

Related Parties

filerCIK 0001376355

Filing Metadata

Form type: 4
Filed: Oct 23, 8:00 PM ET
Accepted: Oct 24, 4:15 PM ET
Size: 24.0 KB

View on SEC.gov